Clene(CLNN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 CLENE REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline ● CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL Responders) demonstrated significant clinical improvements in survival, functional status (slowed ALSFRS-R decline), and combined function ...